Cite Filings / SYRE / 0001628280-26-012785

Feed Companies Filings Check

Sign in

POS AM

Post-effective Amendment for Registration Statement

Spyre Therapeutics, Inc. Filed 2026-02-27 Acc 0001628280-26-012785

Documents 1

POS AM Post-effective Amendment for Registration Statement , spyre-posamonsx3.htm

Around this filing

2026-03-03 4 Chief Financial Officer sold 2,500 shares at an average $40.65 ($101,620)
2026-03-02 144 Sale of Securities
2026-02-27 EFFECT Notice of Effectiveness
2026-02-27 POS AM Post-effective Amendment for Registration Statement
2026-02-25 CORRESP Correspondence Between Filers and SEC Staff
2026-02-25 UPLOAD SEC-generated Letter
2025-03-07 POS AM Post-effective Amendment for Registration Statement

Link to a passage

Paste a passage to link it

At least 12 characters, not counting spaces, so the link points to one passage.

External

SEC EDGAR (opens in new tab)

Loading spyre-posamonsx3.htm…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…